Vancouver, British Columbia–(Newsfile Corp. – November 19, 2020) – Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant“) or (the “Company“) is pleased to announce that its majority owned subsidiary NeonMind Biosciences Inc. (“NeonMind“) has now commenced a psilocybin preclinical trial examining psilocybin as a potential treatment to promote and cause weight loss and to reduce food cravings (the “Trial“) after obtaining Health Canada approval. The Trial is being conducted by the University of British Columbia pursuant to a fee for service agreement.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68546
Powered by WPeMatico
